Awaiting product image

Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015

$995.00 – $1,990.00

SKU: KLI2691449 Category: Pages: 230

Description

What Will The Pharmaceutical Market Look Like in the Next Five Years?
In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals — the companies that produce the lion’s share of industry revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

This Kalorama Information market research report, Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015 captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.

Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years – Pfizer, Merck and Novartis. These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies. The result of all interest in biological solutions to major diseases? In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact.

Key Issues and Trends in the Industry
Issues and Trends discussed in this report include:

  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Biosimilar Development
  • Aging Populations
  • Mergers, Acquisitions, and Collaborations
  • Contributors to R&D Success
  • R&D Spending Trends
  • The Role of Contract Research Organizations
  • Sustainability in a Changing Pharmaceutical Industry

Also, despite an in-depth interview process and complete review of company financials, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical and biopharmaceutical sales are not discussed.

In this comprehensive look a the pipeline of major companies, Kalorama Information presents an accurate picture of the marketplace today, including

 

  • Market Estimates by Major Drug Category, including:
  • Cardiovascular/Blood
  • Neurotherapeutics
  • Infection
  • Oncology
  • Respiratory/Inflammatory
  • Gastrointestinal
  • Other 
  • Discussion of Marketplace Trends
  • Pipeline Analysis of Major Pharmacos
  • Detailed Company Profiles
  • Comparison of Market at Current Growth Versus Impact of Late-Stage Products
  • Biopharmaceutical Market Breakdown
  • Best-Selling Biopharmaceutical Products
  • Regulatory Activity and Market Impact 

    Kalorama Information’s market research into this topic is based on review of government filings and company literature, but also interviews with executives and experts, and the perspective of an analyst who has authored scores of reports in this industry.


    Late Stage Product Development of the Top 50 Companies
    50 top companies make up over 90% of the world biopharmaceutical market; The top three companies have nearly a quarter of global sales in 2009.

    Kalorama looks at each key player’s late-stage pipeline in detail. The top 50 companies discussed in this report include:

    • Abbott
    • Actelion
    • Alcon, Inc.
    • Allergan
    • Amgen
    • Astellas
    • AstraZeneca
    • Baxter International
    • Bayer
    • Biogen
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene Corp.
    • Cephalon
    • Chugai Pharmaceutical
    • CSL
    • Daiichi Sankyo
    • Dainippon
    • Eisai
    • Eli Lilly & Co.
    • Endo
    • Forest
    • Genzyme
    • Gilead Sciences
    • GlaxoSmithKline
    • Hospira
    • Johnson & Johnson
    • Lundbeck
    • Menarini
    • Merck
    • Merck KGaA
    • Mitsubishi Tanabe Pharma
    • Mylan
    • Novartis
    • Novo Nordisk
    • Nycomed
    • Ono Pharmaceutical Co.
    • Otsuka Pharmaceutical
    • Pfizer
    • Procter & Gamble
    • Purdue Pharma
    • Roche
    • Sanofi-Aventis
    • Servier
    • Shionogi
    • Shire
    • Takeda
    • TEVA
    • UCB
    • Watson

Table of Contents

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Potential Market Opportunity
  • Issues and Trends Affecting Market
  • Leading Companies

CHAPTER TWO: INTRODUCTION

  • Global Pharmaceutical Market
  • Pharmaceutical Research & Development Overview
    • Clinical Trial Costs

CHAPTER THREE: ISSUES AND TRENDS

  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Pediatric Extensions
  • Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
  • Aging Population
  • Mergers, Acquisitions, and Collaborations
  • Contributors To R&D Success
  • R&D Spending
  • The Role of Contract Research Organizations
  • Sustainability in a changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

  • Introduction
  • Pfizer, Inc./Wyeth (merged in 2009)
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Merck & Co., Inc.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Novartis AG
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Roche Ltd.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Sanofi-Aventis
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • AstraZeneca plc
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • GlaxoSmithKline plc
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Johnson & Johnson
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Eli Lilly & Company
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Bristol-Myers Squibb Company
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Abbott Laboratories
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Takeda Pharmaceutical Co., Ltd.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Bayer AG
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Amgen, Inc.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Boehringer Ingelheim GmbH
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • TEVA Pharmaceutical Industries, Ltd.
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Astellas
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Daiichi Sankyo
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Novo Nordisk
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline
  • Eisai
    • Overview
    • Financial Performance and Investments
    • Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST

  • Introduction
  • Otsuka
    • Late Stage Pipeline
  • Merck KGaA
    • Late Stage Pipeline
  • Gilead Sciences
  • Late Stage Pipeline
  • Mylan
    • Pipeline
  • Baxter International
    • Late Stage Pipeline
  • Chugai Pharmaceutical Company, Ltd.
    • Late Stage Pipeline
  • Mitsubishi Tanabe
    • Late Stage Pipeline
  • Servier, Les Laboratories
    • Pipeline
  • UCB SA
    • Late Stage Pipeline
  • Allergan
    • Late Stage Pipeline
  • Forest Laboratories
    • Late Stage Pipeline
  • Nycomed International
    • Late Stage Pipeline
  • Genzyme Corporation
    • Late Stage Pipeline
  • Biogen Idec
    • Late Stage Pipeline
  • Hospira
    • Late Stage Pipeline
  • Watson
    • Pipeline
  • CSL Limited
    • Late Stage Pipeline
  • Alcon
    • Late Stage Pipeline
  • Shire
    • Late Stage Pipeline
  • Celgene Corporation
    • Late Stage Pipeline
  • Lundbeck
    • Late Stage Pipeline
  • Shionogi & Co., Ltd.
    • Late Stage Pipeline
  • Menarini Group
    • Late Stage Pipeline
  • Dainippon Sumitomo Pharma, Co., Ltd.
    • Late Stage Pipeline
  • Cephalon
    • Late Stage Pipeline
  • Actelion
    • Late Stage Pipeline
  • Procter & Gamble
  • Endo Pharmaceuticals
    • Late Stage Pipeline
  • Ono Pharmaceutical Co.
    • Late Stage Pipeline
  • Purdue Pharma
    • Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST

  • Overview
  • Company Analysis
  • Pipeline Snapshot: Top 50 Companies
  • Current Market Value
  • Market Forecast

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKETBiopharmaceutical Companies

Biopharmaceutical Market Forecast APPENDIX: LIST OF COMPANIES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
  • Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Phases of Clinical Drug Development
  • Table 2-2: Components of a Clinical Trial

CHAPTER THREE: ISSUES AND TRENDS

  • Table 3-1: International Population Trend Age 65+
  • Figure 3-1: International Population Trend Age 65+
  • Table 3-2: United States Population Trend Age 65+
  • Figure 3-2: International Population Trend Age 65+
  • Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
  • Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
  • Figure 3-3: Drug Development Cost Progression
  • Table 3-5: Total Industry R&D Spending 2004-2009
  • Figure 3-4: Total Industry R&D Spending 2004-2009

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

  • Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)
  • Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-3: Pfizer’s Late Stage Product Pipeline
  • Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-3: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-5: Merck & Co.’s Late Stage Product Pipeline
  • Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-5: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-7: Novartis’ Late Stage Product Pipeline
  • Figure 4-6: Novartis’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-8: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-7: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-9: Roche’s Late Stage Product Pipeline
  • Figure 4-8: Roche’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-10: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-9: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-11: Sanofi-Aventis’ Late Stage Product Pipeline
  • Figure 4-10: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-12: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-11: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-13: AstraZeneca’s Late Stage Product Pipeline
  • Figure 4-12: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-14: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-13: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-15: GlaxoSmithKline’s Late Stage Product Pipeline
  • Figure 4-14: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-15: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
  • Figure 4-16: Johnson & Johnson’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-17: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009
  • Table 4-19: Eli Lilly’s Late Stage Product Pipeline
  • Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-20: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-19: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-21: Bristol-Myers Squibb’s Late Stage Product Pipeline
  • Figure 4-20: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-22: Abbott’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-21: Abbott’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-23: Abbott’s Late Stage Product Pipeline
  • Figure 4-22: Abbott’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2009 (Millions)
  • Figure 4-23: Takeda’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
  • Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-26: Bayer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-25: Bayer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-27: Bayer’s Late Stage Product Pipeline
  • Figure 4-26: Bayers’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-27: Amgen’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-29: Amgen’s Late Stage Product Pipeline
  • Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-29: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
  • Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-32: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Figure 4-31: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
  • Table 4-33: TEVA’s Late Stage Product Pipeline Figure 4-32: TEVA’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-34: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions)
  • Figure 4-33: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions)
  • Table 4-35: Astellas’ Late Stage Product Pipeline
  • Figure 4-34: Astellas’ Late Stage Product Pipeline by Therapeutic Area
  • Table 4-36: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)
  • Figure 4-35: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)
  • Table 4-37: Daiichi Sankyo’s Late Stage Product Pipeline
  • Figure 4-36: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-38: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)
  • Figure 4-37: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)
  • Table 4-39: Novo Nordisk’s Late Stage Product Pipeline
  • Figure 4-38: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
  • Table 4-40: Eisai’s Total Company Revenue and R&D Spending 2007-2009 (Thousands)
  • Figure 4-39: Eisai’s Total Company Revenue and R&D Spending 2007-2009
  • Table 4-41: Eisai’s Late Stage Product Pipeline
  • Figure 4-40: Eisai’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER FIVE: COMPANIES OF INTEREST

  • Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales
  • Table 5-2: Otsuka Pharmaceutical’s Late Stage Product Pipeline
  • Figure 5-1: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-3: Merck KGaA’s Late Stage Product Pipeline
  • Figure 5-2: Merck KGaA’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-4: Gilead Sciences’ Late Stage Product Pipeline
  • Figure 5-3: Gilead Sciences’ Late Stage Product Pipeline by Therapeutic Area
  • Table 5-5: Baxter International’s Late Stage Product Pipeline
  • Figure 5-4: Baxter International’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-6: Chugai Pharmaceutical’s Late Stage Product Pipeline
  • Figure 5-5: Chugai’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-7: Mitsubishi Tanabe’s Late Stage Product Pipeline
  • Figure 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-8: UCB Pharma’s Late Stage Product Pipeline
  • Figure 5-7: UCB’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-9: Allergan’s Late Stage Product Pipeline
  • Figure 5-8: Allergan’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-10: Forest Laboratories’ Late Stage Product Pipeline
  • Figure 5-9: Forest Laboratories’ Late Stage Product Pipeline by Therapeutic Area
  • Table 5-11: Nycomed’s Late Stage Product Pipeline
  • Figure 5-10: Nycomed’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-12: Genzyme’s Late Stage Product Pipeline
  • Figure 5-11: Genzyme’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-13: Biogen Idec’s Late Stage Product Pipeline
  • Figure 5-12: Biogen Idec’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-14: Hospira’s Late Stage Product Pipeline
  • Figure 5-13: Hospira’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-15: CSL’s Late Stage Product Pipeline
  • Figure 5-14: CSL’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-16: Alcon’s Late Stage Product Pipeline
  • Figure 5-15: Alcon’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-17: Shire’s Late Stage Product Pipeline
  • Figure 5-16: Shire’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-18: Celgene’s Late Stage Product Pipeline
  • Figure 5-17: Celgene’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-19: Lundbeck’s Late Stage Product Pipeline
  • Figure 5-18: Lundbeck’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-20: Shionogi’s Late Stage Product Pipeline
  • Figure 5-19: Shionogi’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-21: Menarini’s Late Stage Product Pipeline
  • Figure 5-20: Menarini’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-22: Dainippon Sumitomo’s Late Stage Product Pipeline
  • Figure 5-21: Dainippon Sumitomo’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-23: Cephalon’s Late Stage Product Pipeline
  • Figure 5-22: Cephalon’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-24: Actelion’s Late Stage Product Pipeline
  • Figure 5-23: Actelion’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-25: Endo Pharmaceutical’s Late Stage Product Pipeline
  • Figure 5-24: Endo Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-26: Ono Pharmaceutical’s Late Stage Product Pipeline
  • Figure 5-25: Ono Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
  • Table 5-27: Purdue Pharma’s Late Stage Product Pipeline
  • Figure 5-26: Purdue Pharma’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER SIX: MARKET FORECAST

  • Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)
  • Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
  • Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
  • Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
  • Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
  • Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)
  • Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005-2010
  • Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
  • Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated
  • Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—Potential Impact from Late-Stage Development
  • Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact from Late-Stage Development

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET

  • Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales
  • Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues
  • Table 7-3: Biotechnology Late Stage Development Projects by Company Classification—Pharmaceutical vs. Biotechnology–Market Forecast, 2015

 

Related products

Clinical Diagnostics in India: Market Analyses and Participant DirectoryVaccines 2010: World Market Analysis, Key Players, and Critical Trends in a...